Life sciences · 2026
Integrative bioinformatics and machine learning combined with experimental validation in a doxorubicin-induced model identify BACH2, NXPH4, CD1E, and LIF as sodium overload-related molecular signatures in dilated cardiomyopathy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Shuai, Yu Wei, Ma Bin, Xu Anchen, Zeng Yiyao, Tan Xin, Wang Xiangyu, Fan Huimin, Nong Yuxin, Zhang Hangyao, Chen Ziliang, Jiang Yufeng, Song Yahui, Zhou Yafeng
Аннотация
INTRODUCTION: Dilated cardiomyopathy (DCM) is a leading cause of heart failure and remains a major clinical challenge due to its complex etiology and lack of effective targeted therapies. Sodium overload-induced necrosis, a recently described form of regulated cell death, has emerged as a novel contributor to cardiovascular injury, but its role in DCM remains poorly defined.
AIMS: This study aimed to elucidate the molecular signatures of sodium overload-associated cell death and explore their diagnostic and therapeutic relevance in DCM.
MATERIALS AND METHODS: We systematically integrated four publicly available transcriptomic datasets (GSE226801, GSE116250, and GSE141910) from human myocardial tissues and in vitro sodium-overload models to identify sodium overload-associated death-related genes (DRGs). Machine learning algorithms were used to screen and validate key hub genes. Experimental validation was performed in a doxorubicin-induced DCM mouse model using Western blotting, quantitative PCR, and immunohistochemistry. Drug-gene interaction analysis was conducted using the Comparative Toxicogenomics Database (CTD).
KEY FINDINGS: Four hub genes-BACH2, NXPH4, CD1E, and LIF-were identified as central regulators linking sodium overload to DCM pathogenesis. A diagnostic model incorporating these genes showed robust discrimination between DCM patients and healthy controls across multiple datasets. Furthermore, abrine was identified through CTD analysis as a potential therapeutic candidate capable of simultaneously targeting all four hub genes.
SIGNIFICANCE: This study uncovers a novel mechanistic link between sodium overload-induced regulated necrosis and DCM progression. The findings provide new molecular insights into cardiomyocyte death and inflammation in DCM and propose candidate biomarkers and drug targets for precision therapy.
AIMS: This study aimed to elucidate the molecular signatures of sodium overload-associated cell death and explore their diagnostic and therapeutic relevance in DCM.
MATERIALS AND METHODS: We systematically integrated four publicly available transcriptomic datasets (GSE226801, GSE116250, and GSE141910) from human myocardial tissues and in vitro sodium-overload models to identify sodium overload-associated death-related genes (DRGs). Machine learning algorithms were used to screen and validate key hub genes. Experimental validation was performed in a doxorubicin-induced DCM mouse model using Western blotting, quantitative PCR, and immunohistochemistry. Drug-gene interaction analysis was conducted using the Comparative Toxicogenomics Database (CTD).
KEY FINDINGS: Four hub genes-BACH2, NXPH4, CD1E, and LIF-were identified as central regulators linking sodium overload to DCM pathogenesis. A diagnostic model incorporating these genes showed robust discrimination between DCM patients and healthy controls across multiple datasets. Furthermore, abrine was identified through CTD analysis as a potential therapeutic candidate capable of simultaneously targeting all four hub genes.
SIGNIFICANCE: This study uncovers a novel mechanistic link between sodium overload-induced regulated necrosis and DCM progression. The findings provide new molecular insights into cardiomyocyte death and inflammation in DCM and propose candidate biomarkers and drug targets for precision therapy.